IBRX: ImmunityBio Inc - Common Stock

IBRX新闻

• 15:30 Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
• 15:30 Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
• 21:49 ImmunityBio: ANKTIVA Is Real, The Valuation Isn't (NASDAQ:IBRX)
• 06:10 BUZZ Investing: Markets Look Through Intra-Period Volatility
• 14:53 IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
• 12:50 ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
• 21:10 Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
• 17:20 ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug - ImmunityBio
• 12:30 ImmunityBio: Revisiting My Bearish Call After A 250% Rise (Upgrade) (NASDAQ:IBRX)
• 13:20 BUZZ Investing: BUZZ Lags As Market Leadership Broadens
• 15:07 ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold (NASDAQ:IBRX)
• 18:29 Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now - Lucid Group (NASDAQ:LCID), SoundHound AI (NA
• 08:07 ImmunityBio Stock: A Long-Term Bull Case Worth Watching (NASDAQ:IBRX)
• 11:56 ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
• 17:29 IBRX and the BCG Shortage: Deals That Could Expand Demand
• 17:25 IBRX Stock Outlook After Q1 Results and a New FDA Review
• 17:21 ImmunityBio: Anktiva Explained and What Comes Next
• 04:06 Undercovered Stocks: Cerebras Systems, Infleqtion, Duos Technologies And More
• 13:53 FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy